Drug Profile
Anti-CD44 monoclonal antibody A3D8
Alternative Names: A3D8Latest Information Update: 26 Apr 2007
Price :
$50
*
At a glance
- Originator Duke University Medical Center
- Developer NEXTherapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; HIV-1 infections; Myeloid leukaemia
Most Recent Events
- 26 Apr 2007 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
- 26 Apr 2007 Discontinued - Preclinical for Myeloid leukaemia in France (unspecified route)
- 26 Apr 2007 Discontinued for HIV-1 infections in USA (unspecified route)